Background Intraventricular haemorrhage is a subtype of intracerebral haemorrhage, with 50% mortality and serious disability for survivors. We aimed to test whether attempting to remove intraventricular haemorrhage with alteplase versus saline irrigation improved functional outcome.
Introduction
In patients with spontaneous intracerebral haemorrhage, intraventricular haemorrhage is associated with devastating consequences. [1] [2] [3] [4] Mortality is reported to be greater than 50%, with fewer than 20% of survivors having good functional outcomes. Mortality and function seem to be altered if thrombolysis is used. 5, 6 Systematic review and meta-analysis suggest removal of intraventricular haemorrhage improves survival and long-term functional outcome by relieving acute obstructive hydrocephalus and reducing neurotoxicity. [5] [6] [7] [8] [9] We hypothesised that small intracerebral haemorrhage with large intraventricular haemorrhage describes a subgroup of patients whose severe prognosis is reversible. 1, 6 Thus, we organised the phase 3 Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Haemorrhage (CLEAR III) trial.
Preliminary data showed that alteplase (Genentech Inc, San Francisco, CA, USA) can safely remove clot from the ventricle in patients with an extraventricular drain, if precautions are taken to avoid reactivating brain bleeding. [10] [11] [12] [13] Therefore, in patients with intra ventricular haemorrhage and an extraventricular drain, we tested the hypothesis that irrigating the ventricle with alteplase would improve functional outcome as measured by a modifi ed Rankin Scale (mRS) score 0-3 (mRS ≤3, so-called good outcome) compared with normal saline (0·9%).
Methods

Study design and participants
In this multicentre, randomised, prospective phase 3 trial (CLEAR III ) 13 done at 73 sites in Brazil, Canada, Germany, Hungary, Israel, Spain, the UK, and the USA, following
Research in context
Evidence before this study We searched the literature from Jan 1, 1950, until Nov 1, 2015, on PubMed with the terms: IVH, IVH AND ICH, IVH AND TPA, IVH AND thrombolytic, IVH AND cross-sectional, and intraventricular haemorrhage AND treatment. Search fi lters for "adult" and "human subjects" publications were applied and were restricted to English language publications. Meta-analysis of case series, one small multisite trial, and single-site convenience samples suggest mortality and perhaps functional impairment can be mitigated via enhanced clearance of the intraventricular haemorrhage through thrombolysis. Before and after the CLEAR III trial, when caring for patients with a small intracerebral haemorrhage and large intraventricular haemorrhage, clinicians have no class 1 evidence regarding the eff ectiveness of intraventricular haemorrhage thrombolysis with alteplase.
Added value of this study CLEAR III is a randomised, double-blinded study designed to provide a test of the combination of extraventricular drainage and low dose alteplase as a method to remove intraventricular haemorrhage and improve functional outcomes. This multisite study is the fi rst, to our knowledge, to prospectively collect several objective functional performance (modifi ed Rankin Scale [mRS] and extended Glasgow Outcome Scale [eGOS]) as well as patient-based (Euro-QoL [EQ], Stroke Impact Scale [SIS]) measures of satisfaction. Medical care in the intensive care unit was standardised and assessed rigorously. Data were prospectively defi ned and collected in a uniform manner and monitored thoroughly providing evidence of type, intensity, and duration of intensive care unit care required. Precise measurement of intraventricular haemorrhage size occurred in this trial possibly improving estimates of severity and treatment performance. The results of CLEAR III provide a robust estimate of the proportion of patients with mRS 0-3 (about 45-48%) that occurs, if participants are supported until the extraventricular drain is no longer needed. This led to an adjusted (intraventricular haemorrhage size and thalamic location) estimate of treatment eff ect of 3·5% (95% CI -4 to 12). This eff ect size did not diff er between alteplase and saline treatment plans, although case fatality did. The absolute proportion of patients with mRS 0-3 found in all CLEAR III participants compares favourably to the untreated participants in the literature. The study provides detailed evidence that a protocoled approach to remove intraventricular haemorrhage with alteplase is safe and that the 3rd and 4th ventricles open sooner if alteplase is used. A legitimate concern could be raised about greater infection rates due to frequent injections of alteplase or saline in the extraventricular drain; however, infection rates in CLEAR were in the same range as that reported in a meta-analysis of infections from published extraventricular drain series where injections were not given. The data shown characterise substantial variations in current extraventricular drain-related neurosurgical practice. They suggest usefulness of the measures of initial severity (Glasgow Coma Scale [GCS], location, and intracerebral haemorrhage/intraventricular haemorrhage size) and the elements of treatment needed for precise characterisation of prognosis in aggressively treated intraventricular haemorrhage patients. The subgroup analysis suggests increased focus on larger intraventricular haemorrhage and earlier treatment times is appropriate.
Implications of all the available evidence
The trial was neutral on primary outcome of functional improvement. Therefore, we do not think practice should change. Other post-hoc results are consistent with the hypothesis that clot removal saves lives and possibly improves function. The issue of survival with disability is now well defi ned by our primary results and other measures of disability. The secondary results leave open a possible role of intraventricular haemorrhage volume reduction as a biomarker for treatment, with better outcomes more likely achieved with enhanced intraventricular haemorrhage clearance, particularly in patients with larger initial intraventricular haemorrhage volume. The results are consistent with previous convenience reports and meta-analyses showing that good functional outcome can occur in up to 50% of treated patients. The data provide a sound basis to critically redefi ne short-term neurosurgical and intensive care unit management around the task of volume removal. A trial testing these more objective goals is needed, if we are to be assured that aggressive removal of intraventricular haemorrhage is safe and can predictably produce increased independent function and decreased case fatality. Current information suggests as many as 25% of intracerebral haemorrhages have large intraventricular haemorrhage. How many of these patients would be eligible for treatment is not known. An estimate of the full benefi t of intervention will require a combined epidemiological and RCT intervention approach that randomises available participants and collects information about usual care controls. A novel trial would provide a standardised surgical task, treat subjects more rapidly, and require greater care team adherence to the removal of large amounts of the intraventricular haemorrhage, not just removal of enough blood clot to open the 3rd and 4th ventricles. Sharing the full results of CLEAR III is likely to stimulate further investigations of a worldwide problem that is serious, growing, and could be treatable.
local and country ethics approval, we tested a strategy of ventricular clearance with alteplase via extraventricular drains. Although extraventricular drain placement is not standard practice for all cases of intraventricular haemorrhage, it is used to manage hydrocephalus and intracranial pressure. All patients had a clinical diagnosis of obstructive hydrocephalus, and placement of an extraventricular drain pre-trial was a routine clinical care decision. Participants were aged 18-80 years with known symptom onset within 24 h of the initial CT scan confi rming intraventricular haemorrhage and 3rd or 4th ventricle obstruction. Eligibility criteria included supratentorial intracerebral haemorrhage volume 30 mL or less, measured by the ABC/2 method, 18, 19 and clot stability (no measured expansion >5 mL) on repeat CT scan at least 6 h after extraventricular drain placement. 13 Additional eligibility criteria included a historical mRS of 1 or less, no limitations to care, and no ongoing coagulopathy, suspicion of aneurysm, arteriovenous malformation, or other vascular anomaly (see appendix p 5: methodological details of the treatment protocol and inclusion and exclusion criteria for additional details). 13 All data were captured electronically and pertinent source documentation uploaded by local site personnel using an internet-based electronic data capture (EDC) system (VISION, Prelude Dynamics, LLC, Austin, TX, USA). The EDC provided fi eld-level and form-to-form range and value edit checks during data entry. Independent quality assurance monitors (Emissary International, LLC, Austin, TX, USA) used the uploaded source documentation to perform risk-based, remote monitoring of key data variables. Monitored data were then exported by the data management centre where additional data edit checks were applied before form/participant fi nalisation. Site personnel were notifi ed of and responded to data discrepancies identifi ed during these review processes with the EDC system query tool, with resulting data corrections captured by the electronic audit trail.
Randomisation and masking
All participants and trial personnel, except for the local and central pharmacists and the unblinded statistician, were masked to treatment assignments. After the local principal investigator determined eligibility and written, informed consent was obtained, site personnel randomly assigned patients (1:1) within 72 h of ictus, using a webbased enrolment system (VISION, Prelude Dynamics, LLC, Austin, TX, USA) that generated a treatment allocation and emailed the treatment assignment code directly to the local, trained pharmacist. All other site and coordinating centre personnel remained masked to allocation. After 100 participants were assigned by simple randomisation, a Pocock-Simon 14,15 covariate adaptive algorithm was implemented to balance study groups by baseline intraventricular haemorrhage size (≤20 mL, 20-50 mL, and >50 mL, measured on the diagnostic CT) and intracerebral haemorrhage location (thalamus or other, determined by centralised CT reading). Imbalances in these factors were determined at each enrolment, and patients were randomised with a weighted coin (80/20) favouring assignment to the treatment group, which improved balance in intracerebral haemorrhage location and intracerebral haemorrhage size. 6, 13, 14 To ensure treatment balance at the site, patients were adaptively randomised only after a given site had recruited two saline and two alteplase patients. All participants remained masked during data collection and interim analyses. Masking was assessed by an external monitor.
Procedures
Participants received up to 12 doses, 8 h apart, of 1 mg alteplase or 0·9% saline via the extraventricular drain. CT scans were obtained every 24 h throughout dosing. All participants were managed using the American Heart Association recommendations for the treatment of spontaneous intracerebral haemorrhage as the basis for a standard approach to airway, ventilation, intracranial pressure monitoring, sedation, and pharmacological treatment of mass eff ect. 16, 17 Investigators were asked to remove as much clot as possible, until a stopping point was obtained: 3rd and 4th ventricles open; intraventricular haemorrhage mass eff ect relieved; 80% of clot removed; or 12 doses given.
To optimise accuracy and minimise investigator bias, clot volumes were analysed by a core laboratory using semi-automated segmentation and Hounsfi eld thresholds. 18 This was done with OsiriX software (version 4.1, Pixmeo; Geneva, Switzerland) on DICOM images of each participant's stability and daily scans. This approach has been validated for accuracy and inter-rater reliability. 18, 19 Core laboratory values were used in all analyses. Core lab defi ned location as either thalamus or other (lobar, putamen, caudate).
Participants had an NIHSS assessment at day 7, clinic visits on days 30, 180, and 365, and phone contacts at days 90 and 270. A site-identifi ed, certifi ed examiner assessed the mRS (a score of 0 indicates no symptoms, 5 indicates severe disability, and 6 indicates death), extended Glasgow Outcome Scale (eGOS; eight-level disability scale from 8 [upper good recovery] to 1 [death]), Barthel Index (0 to 100 daily activities scale with 0 indicating no activities performed and 100 all activities performed), Stroke Impact Scale (SIS; self-reported scale of 16 activity domains from 1 [most impaired] to 5 [not impaired]), and National Institutes of Health Stroke Scale (NIHSS, clinic visits only; scores range from 0 to 42, with higher scores indicating a more severe neurological defi cit). CT was repeated at 30 and 365 days. The mRS assessment, the primary outcome, was video-recorded and sent to a core laboratory (Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK) for blinded assessment by an independent panel of experts. 13 All other assessments were secondary. Full details of mRS, eGOS, and NIHSS are given in the appendix (pp 7-10).
See Online for appendix
Outcomes
The primary aim was to assess clinical effi cacy of extraventricular drain plus alteplase by estimating the diff erence in the proportion of centrally adjudicated mRS scores, dichotomised as 3 or less versus more than 3, at 180 days. We estimated the average benefi t comparing treatment versus control, using the intention to treat (ITT) principle. Specifi cally, we estimated the diff erence between the probability of an mRS score of 3 or less at 180 days, referred to as a good outcome, comparing alteplase versus saline. In accordance with the literature on covariateadaptive randomised designs, the estimate of the adjusted treatment eff ect was based on a weighted average of the diff erence in proportions for each of the six strata defi ned by the possible baseline combinations for covariates used in randomisation: intraventricular haemorrhage volume and intracerebral haemorrhage location. Weights were set proportional to the number in each stratum (pooled across groups). The 95% CI was computed by the non-parametric bias corrected and accelerated (BCa) bootstrap method, 20 such that the covariate-adaptive design is adhered to in each resampled (ie, bootstrap replicated) data set. Multivariable logistic regression models were used to estimate the conditional eff ect of treatment on good mRS outcome for baseline variables.
For the planned secondary effi cacy analyses, we used Kaplan-Meier time-to-event analysis to estimate the survival functions and the log-rank test to compare survival by treatment; and the logistic model relating clot removed to mRS 0-3 proportion was used (appendix p 24). These models were informed by univariate regression and well established clinical and epidemiological considerations of the important prognostic factors of age, initial Glasgow Coma Scale (GCS) score (scores range from 3 to 15, with lower scores indicating reduced levels of consciousness), intraventricular haemorrhage size as a continuous variable, and the results of the planned intervention, clot removal. Intensity of ICU management by treatment type was compared via χ² or Fisher's exact test, as appropriate. Results of planned analyses of key demographic subgroups for heterogeneity of treatment eff ect are presented: intraventricular haemorrhage and intracerebral haemorrhage size, location, GCS, age, sex, and ethnic origin.
Post-hoc analyses were done for two unexpected but clinically important fi ndings: 1) when the number of participants in the mRS 5 category at 180 days was inspected for disproportion, a treatment comparison was made; and 2) when inspection of protocol-associated clot removal showed that alteplase achieved the hypothesised diff erential removal for participants with intraventricular haemorrhage volume >20 mL but not in the group with <20 mL, subgroup by treatment group was undertaken. Interaction terms for treatment by baseline intraventricular haemorrhage stability volume at 20 mL were considered. No correction for multiplicity was applied, because secondary analyses were considered hypothesis generating.
The safety aim of the trial was to achieve near total clot dissolution without procedure-related safety events endangering subjects beyond the risks associated with intensive medical treatment. 21 Analyses tested the null hypothesis that use of alteplase is safe for the treatment of intraventricular haemorrhage, relative to standard care of extraventricular drain alone under prespecifi ed thresholds for 30-day case fatality (40%), symptomatic rebleeding (25%), and bacterial brain infection (20%). We tested these three thresholds and all safety event rates as interim analyses by the unblinded statistician (ES) after 100, 175, 250, and 350 participants were enrolled. A fi nal analysis was then done for the full 500 participants over 180 days with Fisher's exact test and reviewed with the DSMB. The overall occurrence rate of serious adverse events was tested between the two treatment groups.
End of treatment (EOT) was defi ned as 24 h after the last dose. 18 Additionally, area under the curve (AUC) of the intraventricular haemorrhage time course from stability to EOT was calculated with the trapezoidal rule to quantify clot removal over time. AUC values were normalised by the time elapsed from stability to EOT, to account for variability in treatment times. Logistic and Cox regression analyses were done to evaluate the relation between intraventricular haemorrhage removal, represented by the normalised AUC of intraventricular haemorrhage clot on mRS ≤3, and 180-day case fatality, respectively, after adjustment for intracerebral haemorrhage clot location, age, intracerebral haemorrhage volume at stability, and randomisation GCS.
Statistical analysis
The trial planning was informed by data from the previously completed phase 2 CLEAR studies, which recorded 30-day outcomes. 6 Sample size planning assumed an average removal diff erence attributable to total alteplase exposure of 12 mL. The sample size of CLEAR III was planned to be 250 patients per group to provide at least 82% power to detect a risk diff erence of 13% in the proportion of good outcome from extraventricular drain plus alteplase treatment compared with control, assuming a 22% proportion of good outcome among controls.
The conjectured risk diff erence and good outcome rate under control were based on extrapolating from the previously completed phase 2 CLEAR studies, which recorded baseline intraventricular haemorrhage clot volume and location (for intracerebral haemorrhage) and 30-day mRS outcomes. 6 To do this, models were fi rst fi t using the data from these studies, and then used for simulating hypothetical trials at sample size 500 as described in the appendix (p 13).
We present data in three groups: the planned ITT primary effi cacy analyses of functional outcome; additional mRS effi cacy analyses including other mRS analyses of various cut points and secondary analyses of case fatality, clot removal, and ICU care; and safety. Adjusted analyses are indicated in the appendix (p 19). The primary and key secondary analyses were designated in 2008, at the start of the trial.
All data analyses were done with two-sided tests with a type I error rate of 0·05, done with the statistical packages STATA 13.0 or higher (STATA Corp, College Station, TX, USA) and R version 3.2 (R Foundation for Statistical Computing, Vienna, Austria). All data are presented as median (IQR), unless otherwise specifi ed.
Role of the funding source
The principal investigator (DFH) conceived, organised, and executed this trial. He had full access to all study data and had fi nal responsibility for the decision to submit for publication. The sponsor NIH/NINDS provided input regarding the study design during the grant review process and the NIH/NINDS-appointed DSMB provided the same during active recruitment. The NIH/NINDSappointed DSMB and Genentech, Inc. approved the decision to submit the paper for publication.
Results
Between Sept 18, 2009, and Jan 13, 2015, 500 patients were randomised: 249 to the alteplase group and 251 to the saline group, with the last participant completing follow-up on Jan 13, 2016 (fi gure 1). The trial completed with 180-day follow-up data available for analysis from 246 of 249 participants in the alteplase group and 245 of 251 participants in the placebo group. Admission demographics and clinical severity factors are shown in table 1 and were similar between groups. Overall, participants arrived at hospital within mean 1·5 h (IQR 0·8-3·5) of ictus and underwent a CT by 2·3 h (1·4-4·9). Intracerebral haemorrhage clot location was in the thalamus in 293 (59%), other in 161 (32%), and primary intraventricular haemorrhage (no identifi able intracerebral haemorrhage) in 46 (9%). The median baseline intraventricular haemorrhage size was 21·8 mL (IQR 12·7-36·8) and intracerebral haemorrhage size was 7·9 mL (2·5-15·0). Baseline mean arterial pressure and intracranial pressure were similar by group. Participants received the fi rst extraventricular drain at 7·5 h (IQR 5·0-12·0) and bleeding was stable by 43·5 h (26·9-57·9) post ictus.
Randomisation occurred at 52·1 h (IQR 39·1-66·5), with fi rst treatment given 3·0 h (1·7-5·5) later. Five (IQR 3-8) doses of alteplase and 12 (9-12) doses of saline were given. EOT occurred at 2·5 days (1·8-3·7) post randomisation for 
Ictus to fi rst EVD (h) 7·1 (4·5-11·9) 7·9 (5·1-12·0)
Ictus to stability CT (h) 43·1 (25·4-58·8) 44·0 (28·2-57·0)
Ictus to randomisation (h) 51·8 (36·4-65·8) 52·2 (41·2-66·8)
Data are median (IQR) or n (%). *Scores on the Glasgow Coma Scale (GCS) range from 15 (fully conscious) to 3 (deep coma). MAP=mean arterial pressure. GCS=Glasgow Coma Scale. NIHSS=NIH Stroke Scale. IVH=ventricular haemorrhage. ICH= intracerebral haemorrhage. EVD=extraventricular drain. Table 4 shows the safety profi le by group and by the Medical Dictionary for Regulatory Activities (MedDRA) body system classifi cations. Fewer neurological, respiratory, and sudden deaths (found in the MedDRA general disorders classifi cation) were noted in the alteplase group than in the saline group. This is consistent with the hypothesis that early removal of blood corrects a severe life threatening cerebral anatomic defect and possibly limits the structural brain injury as well as limits the eff ects of immobility on cardiorespiratory risks inherent with structural brain injury.
A post-hoc analysis showed a greater proportion of patients with mRS 5 (ie, bedbound) in the alteplase group than in the saline group Removal of clot varied widely, dependent on number and location of extraventricular drains and number of alteplase doses. 82 participants (33%) in the alteplase group and 24 participants (10%) in the saline group achieved the 80% removal endpoint. The planned secondary analysis relating mRS score to the amount and timing of clot removal in all participants showed a signifi cant relation between clot removal (per clot remaining [mL] as measured by normalised AUC) and both mRS ≤3 (adjusted OR 0·96 [95% CI 0·94-0·97]; p<0·0001) and case fatality (adjusted HR of death per mL of time-weighted clot volume remaining 1·03 [95% CI 1·02-1·04]; p<0·0001), adjusted for age, thalamic intracerebral haemorrhage location, stability intracerebral haemorrhage volume, and randomised GCS (appendix p 24). The results of the subgroup analyses prespecifi ed in the protocol are shown in fi gure 4. No p values for interaction were signifi cant.
Discussion
In the CLEAR III trial, irrigation of the ventricles with alteplase via a routine extraventricular drain did not improve functional outcomes in patients with intraventricular haemorrhage. Analyses of our secondary outcome measures, 180 day case fatality, was signifi cantly lower in the alteplase group; however, most of these survivors ended up with severe disability (ie, mRS 4 or 5 or eGOS lower and upper signifi cant disability). Clot removal analyses showed an association between amount of removal and improved odds of mRS ≤3. Alteplase seemed safe when compared with saline. These fi ndings suggest possible value to the concept of removing greater amounts of intraventricular haemorrhage volume. On the face of the current evidence, however, alteplase at the dose of 1 mg every 8 h cannot be recommended as an intervention to improve functional outcome in patients with intraventricular haemorrhage.
There are limitations to this trial. This was the fi rst phase 3 trial of intraventricular haemorrhage thrombolysis and evidence-based standards for participant selection and treatment endpoint did not exist. Current guidelines do not mandate the use, number, or location of extraventricular drain catheters, which are important factors aff ecting the amount of intraventricular haemorrhage removed. Routine practice produced good adherence to extraventricular drain safety, and opening of the midline ventricles occurred but poor adherence to removal of more than 80% intraventricular haemorrhage; this lack of adherence could have limited the stringency of the test of our hypothesis. Not all severity factors are known, so imbalances in severity could have existed. For example, non-specifi c factors (eg, type and extent of intensive care unit care) could have diff ered between the treatment groups and aff ected outcomes. This does not seem likely, because participant severity, "withdrawal of care", and intensive care unit care were similar between groups. CLEAR III was a small sample of current clinical practice taken from the most aggressive end of the treatment spectrum: those participants whose physicians used extraventricular drains and the control intervention represented an aggressive level of care not off ered to every participant with intraventricular haemorrhage. The survival and good functional outcomes observed in the CLEAR III controls was greater than in our previous study 6 or in the expected levels from the general population (where low frequencies of extraventricular drain use are coupled with very high reliance on medical care as the sole supportive intervention for intraventricular haemorrhage). 2, 3, 6, 7, 9 Only convenience sample data exists for outcomes of medically managed patients; thus, our knowledge about risk and benefi t for the intervention in the general population is restricted. Another possible limitation is that the CLEAR III sample might not represent a true general intra ventricular haemorrhage population, rather a milder or more severe population. Assessments of the general population of intraventricular haemorrhage, The 180-day data represent the primary, unadjusted outcome. Corresponding eGOS data for the same timepoints can be seen in the appendix (p 24). In the alteplase group, one participant who was initially thought to be lost to follow-up at day 30 was located and assessed at day 180. mRS=modifi ed Rankin Scale. concurrently performed, have demographics and severity factors matching CLEAR III. They show full population estimates of mortality (40-60%) and low good functional outcome (10-30%) suggesting less intense therapies might not produce as many benefi ts. 2, 5 Finally, the main outcome measure: mRS 0-3 versus mRS 4-6 proportion is only one measure of disability. Further research will be needed to clarify the divergent picture within the more severe disability segments of mRS and eGOS. 22 If survival comes at the cost of living with unacceptable impairment, this or any treatment could be seen as limited in value.
Potential to improve practice is evident with the fi ndings that cerebral perfusion pressure and intracranial pressure are not always controlled by a single extraventricular drain routinely placed into the anatomically largest pool of cerebrospinal fl uid or least bloody site. This is a starting point to investigate multiple catheters where the clot is large, bilateral, trapping the ventricle, or creating a local mass eff ect. Placing a second catheter near or into the largest portion of the clot leads to greater and more rapid removal 23 and possibly greater clinical benefi t. The precise clinical defi nitions for the at-risk population will need to be tested in a surgically standardised trial setting. 24 The signal of benefi t from greater clot removal and the low percentage of participants achieving 80% removal raise the possibility that benefi t of alteplase might be possible if greater clot removal could be achieved and, if it is achieved, more rapidly. As CLEAR III did not show improved rates of good functional recovery with alteplase rather than saline, future investigation will need improved surgical placement of catheters to achieve eff ective clot reduction more frequently and more rapidly. A possible solution is an adaptively designed, effi cacy-to-eff ectiveness trial 25 that shows a better clot removal protocol can be integrated into routine stroke care and tests for infl uence on function, disability, and case fatality.
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